Trials / Completed
CompletedNCT00318994
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 to 60 minutes after a bolus of 1 g IV meropenem given during the induction period of anesthesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Meropenem |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2005-09-01
- Completion
- 2007-05-01
- First posted
- 2006-04-27
- Last updated
- 2017-09-01
Locations
1 site across 1 country: Colombia
Source: ClinicalTrials.gov record NCT00318994. Inclusion in this directory is not an endorsement.